Screener
Kymera Therapeutics KYMR Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Research and development | $119,481 | $78,388 | $217,644 | $158,643 |
| General and administrative | 21,126 | 17,645 | 41,484 | 33,916 |
| Total operating expenses | 140,607 | 96,033 | 259,128 | 192,559 |
| Loss from operations | (75,607) | (84,557) | (159,763) | (158,983) |
| Other income (expense): | ||||
| Interest and other income | 14,477 | 8,051 | 29,459 | 16,968 |
| Interest and other expense | (81) | (108) | (141) | (180) |
| Total other income: | 14,396 | 7,943 | 29,318 | 16,788 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's operating income?
- Kymera Therapeutics (KYMR) reported operating income of -$75.61M in Q2 2026.
- How has Kymera Therapeutics's operating income changed year-over-year?
- Kymera Therapeutics's operating income increased by 10.6% year-over-year, from -$84.56M to -$75.61M.
- What is the long-term trend for Kymera Therapeutics's operating income?
- Over 4 years (2021 to 2025), Kymera Therapeutics's operating income has grown at a 36.5% compound annual growth rate (CAGR), from -$100.53M to -$349.4M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Kymera Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude